^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    CELLSEARCH®

    Company:
    Menarini
    Type:
    FDA Cleared (510k)
    1d
    Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=12, Completed, Northwestern University | Recruiting --> Completed | N=100 --> 12
    Trial completion • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    CELLSEARCH®
    |
    Keytruda (pembrolizumab) • carboplatin
    2d
    EPISPOT Detection of Circulating Prostate Cells Among Adenocarcinoma Patients (clinicaltrials.gov)
    P=N/A, N=361, Completed, Centre Hospitalier Universitaire de Nīmes | Active, not recruiting --> Completed
    Trial completion
    |
    CELLSEARCH®
    3d
    NCI-2020-04920: Personalized Autologous Transplant for Multiple Myeloma (clinicaltrials.gov)
    P1, N=90, Recruiting, Emory University | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    CELLSEARCH®
    |
    melphalan
    7d
    Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=42, Recruiting, Weill Medical College of Cornell University | N=20 --> 42 | Active, not recruiting --> Recruiting
    Enrollment open • Enrollment change
    |
    CELLSEARCH®
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    20d
    Flow Enabled Target Capture Halbach-based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients. (PubMed, Mol Oncol)
    Results show a statistically significant median 1.5-fold increase in CTCs captured with the FETCH system compared with CellSearch, accompanied by a median twofold reduction in non-specifically captured leukocytes. This increase in CTC capture can aid the comprehensive analysis of CTCs in a larger number of patients, further supporting clinical implementation of CTC-based diagnostics.
    Journal • Circulating tumor cells
    |
    EPCAM (Epithelial cell adhesion molecule)
    |
    CELLSEARCH®
    22d
    ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma-cfDNA of advanced breast cancer patients: A feasibility proof-of-concept study. (PubMed, Mol Oncol)
    Concurrent ESR1 mutations and methylation were identified in six cases, suggesting combined genetic and epigenetic mechanisms of endocrine resistance. Overall, CTC-derived genomic DNA showed higher sensitivity for detecting ESR1 mutations than plasma ctDNA, supporting the potential value of CTC analysis for characterizing endocrine resistance in advanced BC.
    Journal • Circulating tumor cells
    |
    ER (Estrogen receptor)
    |
    ER positive • ESR1 mutation
    |
    Guardant360® CDx • CELLSEARCH®
    22d
    CAPT CTC: Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=54, Recruiting, Institut Claudius Regaud | N=36 --> 54 | Trial completion date: May 2026 --> Nov 2026 | Trial primary completion date: May 2026 --> Nov 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 negative
    |
    CELLSEARCH® • Parsortix Liquid Biopsy
    1m
    ECOG-ACRIN 5103: Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=4994, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    CELLSEARCH®
    |
    Avastin (bevacizumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    1m
    PD-L1-positive circulating tumor cells associate with tumor malignancy and impaired circulating immunity in patients with gastrointestinal tumors. (PubMed, Sci Rep)
    These findings indicate that PD-L1+CTCs reflect tumor-driven immune suppression and may facilitate metastatic spread. Therefore, PD-L1+CTCs should be considered as promising prognostic biomarkers and may provide a rationale for early immunotherapy.
    Journal • Circulating tumor cells • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    CELLSEARCH®
    1m
    Analytical approaches for the isolation and characterisation of circulating tumour cells in clinical practice. (PubMed, Clin Chim Acta)
    Integration with other circulating biomarkers, such as circulating tumour DNA and exosomes, promise enhanced prognostic and diagnostic accuracy. Standardization of protocols and validation in clinical samples will be critical for translating these technologies into routine oncology practice.
    Review • Journal • Circulating tumor cells
    |
    CELLSEARCH®
    2ms
    Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=97, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    CELLSEARCH®
    |
    temozolomide • veliparib (ABT-888)
    2ms
    Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=52, Recruiting, Weill Medical College of Cornell University | Active, not recruiting --> Recruiting | N=37 --> 52
    Enrollment open • Enrollment change
    |
    CELLSEARCH®
    |
    Keytruda (pembrolizumab) • enzalutamide • Ac-225 rosopatamab tetraxetan (CONV01-α)